The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Randomized phase II trial evaluating the efficacy of zolbetuximab in the second-line for claudin18.2 positive advanced gastric/EGJ cancer patients previously treated with zolbetuximab and platinum-based chemotherapy (ZELDA trial).
 
Koji Ando
Honoraria - Merck
 
Chiaki Inagaki
Stock and Other Ownership Interests - Eisai
Speakers' Bureau - Daiichi Sankyo/UCB Japan; MSD; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Astellas Pharma; Epochal Precision Anti-Cancer Therapeutics; Ono Pharmaceutical
 
Yukiya Narita
Consulting or Advisory Role - Astellas Pharma; Daiichi Sankyo/Astra Zeneca
Speakers' Bureau - Astellas Pharma; BeOne; Bristol-Myers Squibb; Daiichi Sankyo/Astra Zeneca; Lilly; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo/Astra Zeneca (Inst); Ono Pharmaceutical (Inst)
 
Mitsuhiro Furuta
Honoraria - Astellas Pharma; Bristol-Myers Squibb Company; Lilly Japan; Merck; Ono Pharmaceutical; Taiho Pharmaceutical
 
Hidekazu Hirano
Honoraria - Bristol-Myers Squibb Japan; Chugai Pharma; Fujifilm; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical; Teijin Pharma
Research Funding - Amgen (Inst); BeiGene (Inst); Bristol-Myers Squibb Japan (Inst); Taiho Pharmaceutical (Inst)
 
Taito Esaki
Honoraria - Chugai Pharma; Daiichi Sankyo; Hisamitsu Pharmaceutical; Lilly; MSD; Ono Pharmaceutical; Roche Diagnostics Solutions; Taiho Pharmaceutical; Zeria Pharmaceutical
Research Funding - ALX Oncology (Inst); Amgen (Inst); Asahi Kasei (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); Jazz Pharmaceuticals (Inst); MSD (Inst); Nihonkayaku (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst)
 
Kenta Murotani
No Relationships to Disclose
 
Hisato Kawakami
Honoraria - Amgen; Astellas Pharma; Bristol-Myers Squibb Japan; Chugai/Roche; Daiichi Sankyo; GlaxoSmithKline; Lilly Japan; Merck Serono; MSD K.K; Nippon Kayaku; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Pharmaceutical
Consulting or Advisory Role - Abbvie; Astellas Pharma; Daiichi Sankyo Co. Ltd.,
Research Funding - Bristol Myers Squibb Foundation (Inst); Eisai (Inst); Kobayashi Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
Patents, Royalties, Other Intellectual Property - MEDICAL & BIOLOGICAL LABORATORIES CO., LTD for Integrin avß6 autoantibody assay kit in the diagnosis of irAE enteritis
 
Eiji Oki
Speakers' Bureau - Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
Research Funding - Guardant Health
 
Kei Muro
Honoraria - Astellas Pharma; Bristol-Myers Squibb; Daiichi Sankyo/UCB Japan; Lilly; MSD; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Chugai Pharma; Ono Pharmaceutical
Research Funding - Amgen (Inst); Chugai Pharma (Inst); MSD (Inst); PRA Health Sciences (Inst); Taiho Pharmaceutical (Inst)